TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: IBS quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Medical Resource Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients with an Unplanned Delay to Surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Time-to-Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival for stage IV colorectal cancers
Endpoint domain: Mortality/survival
Primary endpoint: Time to recurrence for stage I, II or III colorectal cancers
Endpoint domain: Mortality/survival
Primary endpoint: Macular Pigment Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of heart failure mortality
Endpoint domain: Mortality/survival
Primary endpoint: Global Clinical Assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in insulin need
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Behavior assessment ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognition assessment ratings
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Salivary Cotinine-verified Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: head and neck cancer risk factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Agreement between PA imaging system and esophageal biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of PA endoscopic imaging for identification of Barrett's epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of PA endoscopic imaging for identification of Barrett's epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesional ERAP1 levels in psoriatic skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate post-operative imbalance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self Reported Behavioral Automaticity Index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Peripheral Artery Disease Specific Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hemangioma size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale Brown Obsessive-Compulsive Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence or absence of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Social Cognition Task Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Matrix metalloproteinase-1 genotypes polymorphism level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: doubling of serum Cr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: decline of estimated GFR 50% or more by C-G equation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: initiation of renal replacement therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fugl Meyer Assessment Scale (upper extremity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of Virtual Flow Reserve (VFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in MRI of brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Test of Infant Motor Performance (TIMP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in level of physical and mental fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: percent change in initial claudication distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of Variation at 26 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver iron concentration (LIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: heart iron concentration (HIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bone marrow iron content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of high risk HPV and/or abnormal cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of subjects who experience serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: number of subjects who experience adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of C. auris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Seasonality of C. auris infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Drug susceptibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Serum Bactericidal Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers of Serum Bactericidal Antibody Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with abnormal changes in laboratory tests (haematology, clinical chemistry, and urinalysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate Defined as Serum Asparaginase Activity Level >= 0.1 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Asparaginase Activity 14 Days After First Infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune status and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to completion of ED PrEP screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinician-Administered PTSD Scale for DSM-IV Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Release of cardiac enzymes (TnT and CKMB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness assessed by digital images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness assessed by trichoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction towards treatment outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Implant Procedure and Lead Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: FEV1 trajectory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in serum chloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Levels of Free Fatty Acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor Necrosis Factor-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Von Willebrand Factor Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Progression-free survival at six months (PFS-6)
Endpoint domain: Mortality/survival
Primary endpoint: Number of freezes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average duration of freeze
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Function Testing - FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Patients With Accurate Knowledge About Risks and Benefits of Treatment Options
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients Choosing a Treatment Option That Was Values Concordant
Endpoint domain: Life impact
Endpoint subdomain: Decision-making
Primary endpoint: Proportion of participants on adalimumab therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants on adalimumab therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Myocardial calcium-handling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary Qmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Confirmed Annualized Relapse Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counseling satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Invasive prenatal procedures rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Concordance of oligoclonal IgG bands quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of elimination of [14C]-RPC1063
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic- amount of drug excreted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment response of abdominal pain/discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of patients getting good result after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Differences in tooth movement paths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of sepsis patients with elevated plasma-calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the curve receiver operator characteristic (AUC - ROC) for inflammation biomarkers for detecting infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of sepsis patients with bacterial DNA detected in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of taxane-associated acute pain syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in RSA Migrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in Oxford-12 Hip Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in EQ-5D-5L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Patient Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Renal function at M6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: VAS for Lumbar Pain in 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry Disability Index (ODI) - 3th Month
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PICC line tip location
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Controlled Treated Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 7-day quit rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour quit rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' satisfaction with the mindfulness sessions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients who continued meditation practice during the 2 months after study completion
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of sessions that the patient attends
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Thyroid Stimulating Hormone Reference Intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants Completing the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participant Satisfaction With Overall Program
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Usual sodium intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of life relative to bowel function and care
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 90-90 Straight Leg Raise (SLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Comprehension
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time spent with glucose level <70 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bisoprolol residual plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer specific 5 year survival
Endpoint domain: Mortality/survival
Primary endpoint: Probability of response at week 12 conditional on response at week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of response at week 12 conditional on non-response at week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal ablation outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mortality (time and cause)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Achieving a Score of None or Mild by Investigator-Assessed Facial Wrinkle Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a Score of None or Mild by Subject-Assessed Facial Wrinkle Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SCFA Producer Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the LuAE58054 plasma concentration-time curve from time zero to 24h (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Forehead Wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Immediate Post-op Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients in full treatment-free remission 96 weeks after the start of the consolidation period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients in treatment-free remission 48 weeks after starting a second attempt at treatment-free remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAVG safety & tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: HAVG patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sleep Onset
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Area under Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ICEpop CAPability measure for Adults (ICECAP-A)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Stroke and Aphasia Quality of Life Scale (SAQOL - 39)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EQ-5D-5L
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: modified Reintegration to Normal Living (mRNL)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of treatment-emergent adverse event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in laboratory test results (hematology and blood chemistry)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in vital sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for cessation of shivering after bolus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in LV myocardial efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of superselective intracranial intraarterial infusion of Avastin
Endpoint domain: Adverse events/effects
Primary endpoint: Temperature Difference Between Body Sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of probiotic in the stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in diaphragmatic thickness and excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pregnancy-related signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Maternal distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sickle Cell Disease-Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in areas of secondary hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal-Fetal transmission of CMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of deoxyhemoglobin in MR imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 30-day MACCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arthritis impact measurement scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Movements' Total Average Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total Average Time in Performing Exercises With Jintronix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Difficulty Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global Appreciation Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement of Overall Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tasimelteon pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sagittal plane contour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified B+K ultrasound-based tissue-type images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Architecture Pennation Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Architecture Muscle Fiber Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Architecture Muscle Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Disability Assessment for Dementia
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Instrumental Activities of Daily Living Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety of AAV2hAQP1
Endpoint domain: Adverse events/effects
Primary endpoint: Musculoskeletal disease risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Wounds Healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement rate of RVEDV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetics parameter (plasmatic half-life, clearance, ...)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratio of serum drug concentration on MCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of women developed uterine tears
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy in reducing heavy proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time-to-illness resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative recovery measured by fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Benefit Rate (Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) > 4 Month)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Visual field progression using mean deviation (MD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes